Skip to main content

Paired Ends: Karen Bray, Bill Horman, Steve Lombardi, and More


Pacific Biosciences has appointed Karen Bray to vice president of North America sales. Previously, she was a sequencing sales leader at Life Technologies for the Southeast and Mid-Atlantic regions, where she focused on the SOLiD, Ion Torrent, and capillary electrophoresis sequencing systems. She has also had sales positions at Beckman-Coulter, Fisher Scientific, and Whatman. She received a BS in biology from Western Kentucky University and an MBA from the University of Cincinnati.

Complete Genomics has hired Bill Homan as senior vice president and general counsel. His new role includes corporate governance, securities, legal compliance, litigation management, intellectual property management, and supporting executive compensation activities. Previously, he was senior vice president, general counsel, and secretary of Varian from 1999 until it was acquired by Agilent Technologies in 2010. He holds a BS in economics and political science from Virginia Tech and a JD from the University of Virginia.

Real Time Genomics has appointed Steve Lombardi to CEO. Previously, he was president and CEO of Helicos BioSciences, senior vice president of Affymetrix, and vice president of genetic analysis at Applied Biosystems (Life Technologies). He holds a BA in biology from Merrimack College.

Life Technologies
has elected members of its board to serve as directors until the 2013 annual meeting of stockholders. It elected Donald Grimm, Ora Pescovitz, and Per Peterson. In addition, William Longfield has retired from the board.

Population Genetics
has appointed Alan Schafer to CEO. Schafer is an adjunct professor at Imperial College London Business School and was previously the Wellcome Trust's director of science funding. Before that he served as global vice-president of technology development at GlaxoSmithKline and co-founded Hexagen, a functional genomics company that was acquired by Incyte.
The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.